BiotechTube

diclofenac potassium 25 mg tablet + placebo

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Ankle Sprain

Conditions

Ankle Sprain

Trial Timeline

Aug 1, 2012 → Jan 1, 2013

NCT ID
NCT01666197

About diclofenac potassium 25 mg tablet + placebo

diclofenac potassium 25 mg tablet + placebo is a approved stage product being developed by Novartis for Ankle Sprain. The current trial status is completed. This product is registered under clinical trial identifier NCT01666197. Target conditions include Ankle Sprain.

What happened to similar drugs?

2 of 6 similar drugs in Ankle Sprain were approved

Approved (2) Terminated (0) Active (4)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
🔄Diclofenac SodiumNovartisPhase 3
🔄diclofenac diethylamine gel 2.32% + diclofenac diethylamine gel 2.32% + PlaceboNovartisPhase 3
🔄Diclofenac sodium topical gel 1% + PlaceboNovartisPhase 3
✅Non-selective NSAIDS + CelecoxibPfizerApproved
🔄Topical IBU twice daily + Placebo twice daily + Topical IBU three times daily + Placebo three times dailyPfizerPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01666197ApprovedCompleted

Competing Products

7 competing products in Ankle Sprain

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
Diclofenac SodiumNovartisPhase 3
40
Diclofenac diethylamine 2.32% gel + Placebo + Diclofenac diethylamine 2.32% gel / PlaceboNovartisPhase 2
35
diclofenac diethylamine gel 2.32% + diclofenac diethylamine gel 2.32% + PlaceboNovartisPhase 3
40
Diclofenac sodium topical gel 1% + PlaceboNovartisPhase 3
40
Non-selective NSAIDS + CelecoxibPfizerApproved
43
Topical IBU twice daily + Placebo twice daily + Topical IBU three times daily + Placebo three times dailyPfizerPhase 3
40